FEATURES OF CLINICAL COURSE AND TREATMENT STRATEGY FOR PATIENTS SUFFERING FROM BRONCHIAL ASTHMA IN COMBINATION WITH OBESITY



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Obesity is considered to be one of the risk factors for the development of bronchial asthma (BA) and the reasons for lack of control can probably influence on inflammation of respiratory tract. However, the nature of these relationships needs to be clarified. The aim of the research was to characterise it clinically, functionally, allergologically and endocrinologically, to highlight the features of the course and to define the tactics of treating patients suffering from bronchial asthma in combination with obesity. Methods. The research was made on the basis of the National Research Center - Institute of Immunology of Federal Medical-Biological Agency of Russia: both in outpatient and inpatient conditions. A statistical analysis of 367 patients treated in inpatient conditions due to exacerbation of asthma of various severity and different BMI was performed. 40 patients with BA who satisfied all inclusion criteria and did not have exclusion criteria were treated in outpatient conditions. Patients were divided into two groups. The main group consisted of 20 patients suffering from asthma and having a BMI of more than 30 kg/m2. A control group consisted of 20 patients suffering from asthma and having a normal BMI. Results. When the data of the research was analyzed, it was found that the prevalence of obesity among the 367 patients with asthma and being treated in inpatient conditions in 2013-2015 was 44,9% of patients, which is comparable to the prevalence of obesity among the population in general. Conclusions. The data of the patients suffering from asthma and obesity treated both in inpatient and outpatient conditions, was analyzed and it is set that obesity does not affect the severity of the clinical course of asthma. It is shown that obesity does not affect the control of symptoms of asthma.

Full Text

Restricted Access

About the authors

E F Glushkova

NRC Institute of Immunology FMBA of Russia

Email: glushkovaef@gmail.com
24, Kashirskoe Shosse, Moscow, 115478, Russia

N V Shartanova

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

References

  1. GINA, 2015 http://www.ginasthma.org.
  2. Федосеев ГБ, Емельянов АВ, Сергеева ГР, Иванова НИ, Зибрина ТМ, Максименко ИН и соавт. Распространенность бронхиальной астмы и аллергического ринита среди взрослого населения Санкт-Петербурга. Терапевтический архив. 2003;(1):523-526.
  3. Mannino DM. Surveillance for asthma - United States, 1988-1999. MMWR Morb. Mortal. Wkly Rep. 2002;51:1-13.
  4. Официальный сайт ВОЗ. Информационный бюллетень № 307 Май 2011 г.
  5. Минеев ВН, Лалаева ТМ, Васильева ТС, Трофимов ВИ. Фенотип бронхиальной астмы с ожирением. Пульмонология. 2012;(2):1021076
  6. Арутюнов ГП. Лечение атеросклероза: актуальные вопросы стратегии и тактики. Клиническая фармакология и терапия. 1999;(1):3438.
  7. King GG, Brown NJ, Diba C. The effects of body weight on airway caliber. Eur Resp J. 2005;25:896-901.
  8. Shore SA. Obesity and asthma: Possibe mechanisms. J Allergy Clin Immunol. 2008;121:1087-1092.
  9. Шартанова НВ, Глушкова ЕФ. Влияние ожирения на течение бронхиальной астмы. Вопросов больше, чем ответов. Российский Аллергологический Журнал. 2015;(6):5-12.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2017



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies